PRNewsWire
30 May 2026, 18:30 UTC · 17w ago
Verdict
Headline takes no side. We score PGEN +1.00 across three claims — strongly bullish.
+1.00strongly bullish
More positive than 99% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
PAPZIMEOS has been granted seven-year market exclusivity by the FDA as the first and only approved therapy for adult recurrent respiratory papillomatosis (RRP).
So whatA seven-year monopoly in an untapped market for a specific disease provides a high-margin revenue stream with no direct competitors.
More positive than 99% of claims this week
Updated long-term data shows 83% of complete responders maintained their response after 36 months, with some remaining surgery-free beyond 4 years.
So whatDemonstrated long-term durability is critical for adoption and pricing power in rare disease therapies, shifting the standard of care away from surgery.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 93% of claims this week
Precigen estimates there are approximately 27,000 adult RRP patients in the United States.
More positive than 79% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
The company presented positive long-term durability data for PAPZIMEOS and highlighted its seven-year market exclusivity.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
18h ago
+97.2%
Price agrees with the score
$8.56 vs $4.34 close before publication (May 29) · not market-adjusted
PGEN chart →
